Pharmaceutical

Immune Thrombocytopenia by NovelMed Therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval

Immune Thrombocytopeniais under clinical development by NovelMed Therapeutics and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

Jul 1, 2023 - 20:00
Immune Thrombocytopeniais under clinical development by NovelMed Therapeutics and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).
Read the original article

Tags:

Previous Article

SNK-396 by Synerk for Lipid Disorders: Likelihood of Approval

Next Article

Cold agglutinin disease by NovelMed Therapeutics for Acquired (Autoimmune) Hemol...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: How doctors and nurses shape Google’s AI, DEA extends telehealth flexibilities

STAT+: How doctors and nurses shape Google’s AI, DEA ex...

Oct 10, 2023

MaxCyte and Kamau Therapeutics sign platform license agreement

MaxCyte and Kamau Therapeutics sign platform license ag...

Sep 18, 2024

FDA grants access to new class of paediatric diabetes medicine

FDA grants access to new class of paediatric diabetes m...

Jun 21, 2023